Market Trends of Granisetron Industry
The Injection Segment is expected to witness significant growth in the market
Granisetron hydrochloride injection is a serotonin-3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The recommended dosage for granisetron hydrochloride injection in adults is 10 mcg/kg, whereas the recommended dose in pediatric patients two to 16 years of age is 10 mcg/kg. When granisetron is used to prevent nausea and vomiting caused by cancer medicines (chemotherapy), it is usually given 30 minutes before the start of chemotherapy. However, when used to prevent and treat nausea and vomiting caused by surgery, it is usually given 30 seconds before anesthesia or right after surgery if nausea and vomiting begin.
An increase in research studies demonstrating the benefit of intravenous granisetron over other routes is expected to drive segment growth over the forecast period. For instance, as per the article published in July 2023 in Scientific Reports, researchers studied the efficacy of intravenous granisetron versus prophylactic ephedrine in preventing hypotension post-general anesthesia induction in elderly patients. The study showed that administering intravenous granisetron to elderly patients during general anesthesia induction decreased the need for prophylactic ephedrine, thereby aiding in the prevention of post-induction hypotension. Hence, owing to such benefits offered by the granisetron injection, its adoption is expected to rise, leading to segment growth over the forecast period.
Thus, owing to the ease of administration and efficiency, the injection segment is expected to drive growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same During the Forecast Period
North America is expected to witness notable growth in the granisetron market owing to the high burden of cancer cases, increase in the prevalence of gastroparesis, and rise in the adoption of granisetron among cancer patients.
The high prevalence of cancer cases necessitates the requirement for chemotherapy and radiotherapy, which is expected to ultimately drive market growth in the country. For instance, as per the American Cancer Society 2024 report, 2 million cancer cases are estimated to be diagnosed in the United States, a considerable increase from 1.9 million in 2023. The high incidence of cancer indicates the increasing patient visits for chemotherapy and radiotherapy, thereby increasing the demand for granisetron for addressing the symptoms and fueling the growth of the market.
Furthermore, the US government approved various formulations of granisetron for treating cancer-induced vomiting. For instance, as per the July 2023 update by the National Cancer Institute, the guideline suggested that when corticosteroids are not suitable, the recommended approach is to administer nabilone or chlorpromazine alongside ondansetron or granisetron to children undergoing highly emetogenic chemotherapy. As per the same source, in the United States, granisetron is approved in various forms, such as injections, extended-release injections, transdermal patches, and oral tablets for initial and repeat prophylaxis in patients undergoing emetogenic chemotherapy, notably those on high-dose cisplatin regimens.
Thus, owing to the availability of granisetron and the increase in benefits offered by granisetron, the market is anticipated to lead to significant growth in the region during the study period.
